Analysis of the Specific Immune Response after the Third Dose of mRNA COVID-19 Vaccines in Organ Transplant Recipients: Possible Spike-S1 Reactive IgA Signature in Protection from SARS-CoV-2 Infection

Monica Miele 1,2,*†, Rosalia Busà 1,‡, Giovanna Russelli 1, Maria Concetta Sorrentino 3, Mariangela Di Bella 1,2, Francesca Timoneri 1,2, Giampiero Vitale 1,2, Elisa Calzolari 4, Patrizio Vitulo 5, Alessandra Mularoni 6, Pier Giulio Conaldi 1 and Matteo Bulati 1

1 Research Department, Mediterranean Institute for Transplantation and Advanced Specialized Therapies (IRCCS ISMETT), 90127 Palermo, Italy; rbusa@ismett.edu (R.B.); grusselli@ismett.edu (G.R.); mdibella@fondazionerimed.com (M.D.B.); ftimoneri@fondazionerimed.com (F.T.); gvitale@fondazionerimed.com (G.V.); pgconaldi@ismett.edu (P.G.C.); mbulati@ismett.edu (M.B.)
2 RI.MED Foundation, 90133 Palermo, Italy
3 Department of Laboratory Medicine and Advanced Biotechnologies, Mediterranean Institute for Transplantation and Advanced Specialized Therapies (IRCCS ISMETT), 90127 Palermo, Italy; msorrentino@ismett.edu
4 Allergy and Respiratory Diseases, Department of Internal Medicine (DIMI), IRCCS Policlinico San Martino, University of Genova, 16124 Genoa, Italy; ecalzolari@ismett.edu
5 Department for the Treatment and Study of Cardiothoracic Diseases and Cardiothoracic Transplantation, Mediterranean Institute for Transplantation and Advanced Specialized Therapies (IRCCS ISMETT), 90127 Palermo, Italy; pvitulo@ismett.edu
6 Department of Infectious Diseases, Mediterranean Institute for Transplantation and Advanced Specialized Therapies (IRCCS ISMETT), 90127 Palermo, Italy; amularoni@ismett.edu
* Correspondence: mmiele@fondazionerimed.com
† These authors contributed equally to this work.

Abstract: Background: Several studies have indicated that anti-SARS-CoV-2 mRNA vaccinations are less effective in inducing robust immune responses among solid organ transplant recipients (SOTRs) compared with the immunocompetent. The third dose of vaccine in SOTRs showed promising results of immunogenicity, even though clinical studies have suggested that immunocompromised subjects are less likely to build a protective immune response against SARS-CoV-2 resulting in lower vaccine efficacy for the prevention of severe COVID-19. Methods: Serological IgG and IgA were analyzed through ELISA and ELISPOT, respectively. Results: The third dose induced an improvement in antibody response against SARS-CoV-2. Conclusions: We can conclude that serum IgA detection can be helpful, along with IgG detection, for the evaluation of vaccine efficacy, principally in fragile subjects at high risk of infection.

Keywords: mRNA vaccine; solid organ transplant recipients; immune response; IgG; IgA; T cell response; SARS-CoV-2; COVID-19

1. Introduction

Coronavirus disease (COVID-19) is caused by a complex interaction between a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the host immune
response. Observational studies on vaccine effectiveness have demonstrated the efficacy of mRNA vaccines, including Pfizer-BioNTech BNT162b2 and Moderna mRNA-1273, in the prevention of COVID-19-associated hospitalization and severe disease among immunocompetent people [1–4]. However, several studies have indicated that anti-SARS-CoV-2 mRNA vaccination is less effective in inducing robust immune responses among solid organ transplant recipients (SOTRs) on immunosuppressive medication regimens [5–9]. Indeed, studies have reported [9–11] that more than 60% of SOTRs fail to elicit humoral and cellular immunity after two doses of mRNA vaccines. The suboptimal immunogenicity of vaccines in SOTRs after transplantation has already been demonstrated for influenza due to co-morbidity conditions and the effects of the immunosuppressive drugs used [12–14].

A systematic review [15] reported that, among SOTRs, after the mRNA primary vaccination cycle (two doses), non-responder rates ranged from 18 to 100% (35–98% in kidney transplant recipients, 19–63% in liver transplant recipients, 25–88% in heart transplant recipients, and 59–100% in lung transplant recipients). Reports on the third dose in SOTRs showed promising results of immunogenicity [16,17] even though some clinical studies have suggested that immunocompromised subjects are less likely to build a protective immune response against SARS-CoV-2 [5,9,18–20] resulting in lower vaccine efficacy for the prevention of severe COVID-19 [21,22]. In this study, we analyzed humoral and cellular immune responses after the second and third dose of mRNA vaccine and the different factors associated with the mounting of SARS-CoV-2-specific immunity in a cohort of 43 SOTRs. Moreover, we recorded the clinical outcomes of patients who contracted the infection after the third vaccine dose. Our results highlight that the additional third dose resulted in a markedly improved antibody response against SARS-CoV-2. We also reported a strong correlation between specific humoral and cellular responses after the third dose, even though we did not see significant changes in the magnitude of the SARS-CoV-2-specific T cell response. Nevertheless, more than one-third of our cohort of SOTRs contracted the SARS-CoV-2 infection after the third dose of mRNA vaccine. Interestingly, we reported that this group of infected–vaccinated SOTRs, despite eliciting a good SARS-CoV-2-specific IgG response after the third dose, failed to mount an anti-Spike-S1 IgA response, either before or after SARS-CoV-2 infection. These results lead us to hypothesize a possible protective role of serum IgA in the prevention of COVID-19. For this reason, we suggest that serum IgA detection can be helpful, alongside IgG detection, for the evaluation of vaccine efficacy, principally in fragile subjects at high risk of infection, such as SOTRs.

2. Materials and Methods

2.1. Recruitment and Clinical Sample Collection

We prospectively enrolled the first 43 SOTRs received by ISMETT Hospital for post-transplant follow-up, who had received the second dose of mRNA (Pfizer-BioNTech or Moderna) vaccine between January and May 2021 and the third dose between September and December 2021, and from whom peripheral blood mononuclear cells (PBMCs) and serum samples were serially collected. Among these 43 patients, 14 presented COVID-19-like symptoms and tested positive for SARS-CoV-2 RT-PCR (nasopharyngeal/oral swab) after the third dose of the vaccine. Five patients required hospitalization, while nine patients had mild or moderate symptoms and were treated for the infection at home. Characteristics of the population are summarized in Table 1. None of the patients included in the study had a history of PCR-confirmed SARS-CoV-2 infection, neither before nor after the second dose of the vaccine. To monitor infection during the overall period of follow-up, apart from a positive nasopharyngeal swab, we also evaluated the presence of an immune response against the N protein. The anti-N response was determined with the ARCHITECT Quant test (Abbott) using the chemiluminescent assay anti-SARS-CoV-2-N-domain CMIA (IgG and IgM) (Abbott) and SARS-CoV-2 ELISpot against N-peptides mix (see ELISpot paragraph) 3 weeks after the second (T1) and the third dose (T2) (data not shown). Blood, PBMCs, and serum samples were collected at T1 and T2 for the analysis of humoral and cellular responses. We also collected serum samples from SARS-CoV-2-infected SOTRs...
1 month after nasopharyngeal/oral swab negativization (T3). The study was approved by the IRCCS ISMETT Institutional Research Review Board (IRRB/00/21) and by the Ethics Committee of ISMETT and all enrolled patients signed the written informed consent form.

Table 1. Baseline characteristics of SOTRs.

| Variable                                      | SOTRs (n = 43) |
|-----------------------------------------------|----------------|
| Age, mean yr (SD)                             | 54.2 (12.7)    |
| Gender, M (%)                                 | 26 (60.4)      |
| Type of transplant, n (%)                     |                |
| kidney                                        | 11 (25.6)      |
| lung                                          | 14 (32.6)      |
| liver                                         | 10 (23.2)      |
| heart                                         | 7 (16.3)       |
| liver-kidney                                  | 1 (2.3)        |
| Time from transplant, median yr (range)       | 6 (1–27)       |
| Immunosuppressive treatment, n (%),           |                |
| Calcineurin inhibitors $^1$ (3.27 to 12.43 ng/mL) mean ng/mL (SD) | 40 (93), 7.2 (2.0) |
| mTOR inhibitors $^2$ (2.43 to 5.47 ng/mL) mean ng/mL (SD) | 3 (7), 3.6 (1.60) |
| Mycophenolate-mofetil (MMF) (180 to 2000 mg) mean mg (SD) | 30 (69.7), 968.5 (487.6) |
| Steroids (1.25 to 12.18 mg) mean mg (SD)      | 23 (53.5), 5.4 (2.4) |
| Timespan between T1/T2, mean days (range)     | 187.7 (114–244) |
| Timespan between T1/sampling, mean days (range)| 36.51 (15–136) $^3$ |
| Timespan between T2/sampling, mean days (range)| 40.3 (11–132) $^3$ |
| Comorbidities, n (%)                          |                |
| Diabetes                                      | 9 (20.93)      |
| Obesity                                       | 7 (16.27)      |
| Hypertension                                  | 17 (39.53)     |
| Dyslipidaemia                                 | 8 (18.60)      |
| Active or previous smoke                      | 14 (32.56)     |
| Cardiovascular disease                        | 12 (27.90)     |
| Kidney disease                                | 6 (13.95)      |
| Pulmonary disease                             | 6 (13.95)      |
| Gastrointestinal disease                      | 12 (30.23)     |
| Endocrinal disease                            | 7 (16.27)      |
| Hepatopancreatic disease                      | 3 (6.97)       |
| History of malignancy                         | 16 (37.20)     |

$^1$ tacrolimus, $^2$ everolimus, $^3$ $p$-value between timespan between T1/sampling and timespan between T2/sampling was not significant ($=0.480$). Abbreviations: yr, year; SD, standard deviation; M, male; MMF, Mycophenolate-mofetil.

2.2. Detection of SARS-CoV-2 Anti-Spike Immunoglobulins

Anti-Spike IgG and IgA were detected in sera from enrolled subjects. The chemiluminescent immunoassay (CLIA) LIAISON® SARS-CoV-2 S1/S2 IgG (DiaSorin S.p.A., Saluggia, VC, Italy) was used to perform quantitative detection of IgG antibodies against S1 and S2 fragments of the Spike protein. The test was used on the fully automated LIAISON® XL Analyzer (DiaSorin S.p.A., Saluggia, VC, Italy). The SARS-CoV-2 S1/S2 IgG antibody
concentrations were expressed as Binding Antibody Unit (BAU) per ml (BAU/mL), and values > 33.8 BAU/mL were considered positive. The anti-SARS-CoV-2 IgA (EUROIMMUN, PerkinElmer Company, Hong Kong, China) enzyme-linked immunoassay (ELISA) was used for the semi-quantitative detection of IgA antibodies to S1 fragments of the viral surface Spike protein. The test was used on the fully automated EUROIMMUN Analyzer I (EUROIMMUN, PerkinElmer Company). The anti-SARS-CoV-2 ELISA IgA antibody concentrations were expressed as the ratio of the extinction of the sample to that of the calibrator, and the results were graded as follows: Negative (<0.8), Equivocal (≥0.8 to 1.1), and Positive (>1.1).

2.3. SARS-CoV-2 ELISpot Assay

ELISpot assay was used to detect T cell response. We isolated PBMCs from whole blood of studied subjects by density gradient centrifugation using a cell preparation tube with sodium citrate (BD Vacutainer® CPT™) according to the manufacturer’s protocol. PBMCs were counted using the Sysmex XN-2000™ Hematology System. Human IFN-γ ELISpot plus kit (Mabtech AB, Stockholm, Sweden) were used to detect IFN-γ-secreting T cells, according to the manufacturer’s protocol. The assay was performed in duplicate, stimulating 2.5 × 10^5 ± 0.5 × 10^5 PBMCs/mL for 20–22 h, at 37 °C in a 5% CO₂ humidified atmosphere, with 1 µg/mL overlapping peptides spanning the SARS-CoV-2 Spike (Mix I and II, respectively, of 158 and 157 peptides, purity > 90% derived from a peptide scan, 15 mers with 11 aa overlap) or an N protein peptide pool (purity > 90%, JPT Peptide Technologies, Berlin, Germany). The PBMCs were cultured in RPMI 1640 medium (BIOWEST, Nuaillé, France), supplemented with 5% GemCell™ U.S. Origin Human Serum AB (BIOIVT, Westbury, NY, USA) and 1% L-Glutamine (Euroclone, Pero, Italy). A negative control (RPMI + 5% Human Serum AB) and positive controls, such as anti-CD3 and CEFX PepMix (a pool of 176 known peptides from various infectious agents, JPT Peptide Technologies, Germany) were also included. The number of SARS-CoV-2-specific IFN-γ-secreting cells was measured, according to ELISpot guidelines [23], with an ELISpot Reader (Autoimmun Diagnostika (AID) GmbH, Straßberg, Germany) and using ELISpot Software (AID). Mean spot counts for negative control wells were subtracted from the mean of test wells, and the spots are presented as Spot Forming Unit (SFU) per million PBMCs to generate normalized readings. To determine the lower limit for indicating a positive response (cutoff), we considered the mean value of responses of unstimulated wells plus two standard deviations (SDs) (cutoff = 112 SFC/10^6 PBMC).

2.4. Statistical Analysis

Statistical analysis was performed with GraphPad Prism 8. The Wilcoxon matched-pairs signed-rank test was used to compare paired nonparametric data. Correlations were performed using the Spearman’s rank correlation coefficient. Statistical significance was determined as *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.

3. Results

3.1. Characteristics of the Study Population

In this study, 43 SOTRs (26 men, 60%) with a median age of 54 years (IQR, 46–62.3 years), with no history of COVID-19 and a negative SARS-CoV-2 anti-N serology at the time of inclusion, were enrolled. Patients’ baseline characteristics are shown in Table 1. The IS therapy included calcineurin inhibitors (CNI, tacrolimus) (93%, 40/43 patients), mTOR inhibitors (everolimus) (7%, 3/43 patients), Mycophenolate-mofetil (MMF) (69.8%, 30/43 patients), and steroids (53.5%, 23/43 patients).

3.2. The Third Dose of Pfizer-BioNTech BNT162b2 mRNA Vaccine Induces an Improvement in Humoral Response

Serum Spike-specific IgG antibody titers were compared after the second (T1) and third dose (T2) of mRNA vaccine in SOTRs. The proportion of SOTRs with a positive serologic
response was 56% at T1 and 84% at T2. As reported in Figure 1a, we found a significant increase in the median value of Spike-specific IgG after the third dose (2.6-fold change T1/T2), suggesting that an additional dose provides an efficient boost of antibody response against SARS-CoV-2. Indeed, at T1 the median value of specific IgG was 335.40 BAU/mL (IQR, 127.4–811.2; SEM = 101.4), while a median value of 872.0 BAU/mL was reached at T2 (IQR, 331.2–2109.0; SEM = 263.6; p < 0.0001). Thirteen of the 19 patients (68%) who were seronegative (anti-S IgG < 33.8 BAU/mL) at T1 showed seroconversion after the third dose. Moreover, to better characterize the serological response we evaluated the serum Spike-specific IgA antibody levels at the same time point. As depicted in Figure 1b, we observed a slight but significant increase in the median value of specific IgA after the third dose (1.4-fold change T1/T2). Indeed, at T1 the median ratio of specific IgA was 1.0 (IQR, 0.40–4.66; SEM = 0.52), and at T2, 1.4 (IQR, 0.45–7; SEM = 0.59; p = 0.031). Four of the 15 patients (27%) who were seronegative (anti-S IgA < 1.1) at T1 showed seroconversion after the third dose.

Conversely, we observed that the third dose did not induce an increase in the cellular response in SOTRs. Indeed, we noticed a similar trend in Spike-elicited IFN-γ release in the SOTRs, where the spot median value was 129.5 (IQR, 69–254; SEM = 37.3) and 129 (IQR, 49–312; SEM = 39) SFC per 10^6 PBMC cells at T1 and T2, respectively (p = 0.694) (Figure 1c). Particularly, at T1 65% (28/43) of patients mounted a positive T cell response, while at T2 we reported a slight reduction (53%, 23/43) in patients with a positive T cell response. Interestingly, 23/28 SOTRs (82%), who positively raised viral immunity at T1, maintained a Spike-specific T cell response at T2, and two patients without a T cell response at T1, mounted a positive response at T2. As a control, we used CEFX immuno-dominant peptide pools to stimulate PBMC, obtaining similar responses at T1 and T2 (data not shown).

**Figure 1.** Humoral and cellular immune response to SARS-CoV-2 vaccination in SOTRs (n = 43) after the second (T1) and third (T2) dose of Pfizer-BioNTech BNT162b2 vaccine. (a) Comparison of anti-SARS-CoV-2 S1/S2 IgG concentration between T1 (white dots) and T2 (grey dots). Samples with anti-SARS-CoV-2 S1/S2 IgG concentration >33.8 BAU/mL were considered positive. (b) Comparison of anti-SARS-CoV-2 S1 IgA ratio between T1 (white dots) and T2 (grey dots). Ratios ≥ 1.1 were considered positive. (c) T cell responses (IFN-γ ELISpot SFC per 10^6 PBMC) to Spike were compared between T1 (white dots) and T2 (grey dots) in SOTRs. Each dot plot represents the normalized mean spot count from duplicate wells (2.5 ± 0.5 × 10^3 PBMC/well) for each subject after subtraction of the spot count of unstimulated cells. IFN-γ ELISpot > 112 SFC/10^6 PBMC were considered positive. The connection lines represent the antibody value of each subject at T1 and T2, while the dotted line corresponds to the threshold. The significance was determined using the Wilcoxon matched-pairs signed-rank test (two-tailed), **** p < 0.0001, * p = 0.0314.

### 3.3. The Magnitude of Vaccine-Specific T Cell Responses

3.3. The Magnitude of Vaccine-Specific T Cell Responses

The third dose of the Pfizer-BioNTech BNT162b2 mRNA vaccine did not induce a significant increase in the cellular immune response in SOTRs. However, we noticed a similar trend in Spike-elicited IFN-γ release in the SOTRs, where the spot median value was 129.5 (IQR, 69–254; SEM = 37.3) and 129 (IQR, 49–312; SEM = 39) SFC per 10^6 PBMC cells at T1 and T2, respectively (p = 0.694) (Figure 1c). Particularly, at T1 65% (28/43) of patients mounted a positive T cell response, while at T2 we reported a slight reduction (53%, 23/43) in patients with a positive T cell response. Interestingly, 23/28 SOTRs (82%), who positively raised viral immunity at T1, maintained a Spike-specific T cell response at T2, and two patients without a T cell response at T1, mounted a positive response at T2. As a control, we used CEFX immuno-dominant peptide pools to stimulate PBMC, obtaining similar responses at T1 and T2 (data not shown).
3.4. T Cell Response Correlates with IgG Antibody Levels after the Third Vaccination Dose

To better understand whether humoral and cellular responses induced by mRNA vaccines have interdependent effects, we assessed the correlation magnitude existing between the cellular responses against IgG antibody levels after vaccination. At T1 we found a significant correlation between T cell response and IgG ($r = 0.5964$, $p < 0.0001$) (Figure 2a). At T2 we observed a strong significant correlation comparing T cell response with IgG serum levels ($r = 0.9998$, $p < 0.0001$) (Figure 2b). Moreover, as the suboptimal immunogenicity of vaccines in SOTRs due to immunosuppressive (IS) drug treatments is known, we evaluated the correlation between immune responses and IS regimens. Comparing humoral or T cell response versus type, dosage, and level of immunosuppressive (IS) drugs, we did not find any significant correlations (data not shown).

![Figure 2. Correlation of IgG humoral responses against cellular immune response to SARS-CoV-2 vaccination in SOTRs (n = 43) after second (T1) and third (T2) dose of Pfizer-BioNTech BNT162b2 vaccine. (a) Correlation of T cell responses (IFN-γ ELISpot SFC per 10⁶ PBMC) to Spike against anti-SARS-CoV-2 IgG (BAU/mL) at T1 (white dots). (b) Correlation of T cell responses (IFN-γ ELISpot SFC per 10⁶ PBMC) to Spike against anti-SARS-CoV-2 IgG (BAU/mL) at T2 (grey dots). Spearman’s rank correlation (two-sided) was used to test the significance and the p-values and r-values (correlation coefficient) are indicated for each panel, **** $p < 0.0001$.](image)

3.5. Clinical Outcome after the Third Dose

In order to define the real-life efficacy of the third dose of an mRNA vaccine on SOTRs, we evaluated the correlation between immune response and clinical outcomes, such as the severity of disease, hospitalization, and death after SARS-CoV-2 infection. During follow-up, at a median time of 130 days (IQR, 120–169.5 days) after the third dose, 14/43 SOTRs (32% of total) enrolled in our study had contracted SARS-CoV-2 infection. The clinical characteristics of patients are described in Table 2. The virus-infected SOTRs had a median age of 53 (IQR, 41–58 years) and were six lung, three liver, and two heart recipients, with a median time from transplant of 7 years. Nine of them showed mild to moderate symptoms, including fever, pain, cough, and asthenia, which did not need hospitalization, but 1/9 of patients were treated with an antiviral drug to prevent complications. Five SOTRs showed severe symptoms that required hospitalization: 3/5 recovered and 2/5 had a fatal outcome related to COVID-19. The two deceased patients, TxVAC11 and TxVAC19, had been admitted to ICU, the former was treated for ARDS with extracorporeal membrane oxygenation (ECMO), and the latter, who had been previously admitted for ischemic stroke, was treated with non-invasive ventilation. Among the nine patients with mild symptoms who did not require hospitalization, five had an anti-SARS-CoV-2 positive immune response of both T cells and serum IgG, three had either an IgG or T cell positive response, and one showed no detectable immunological response and was treated with antiviral drugs. Among the three hospitalized patients who recovered, two showed only the positive IgG response and were treated with monoclonal antibodies, while one showed only the T cell response and needed antiviral treatment. Finally, the two deceased patients did not show any humoral or T cell responses, neither after the second
nor the third dose. Concerning Spike-specific IgA, we reported a positive serology only in two non-hospitalized patients who recovered, which also presented both IgG and T cell positive responses. Amongst the remaining 29 SOTRs who did not contract the infection, almost all of them mounted at least one type of immune response. Given the heterogeneity of the anti-SARS-CoV-2 immune response after the third vaccination, apart from the two deceased infected patients, we decided to compare the humoral assessment in uninfected– and infected–vaccinated SOTRs to identify predictive biomarkers of clinical outcomes. Interestingly, comparing serum IgG levels at T2, we showed that both groups had a positive specific IgG response with no significant statistical difference \( p = 0.5270 \). As depicted in Figure 3a, the median value in uninfected SOTRs was 872.0 BAU/mL (IQR, 486.7–1927.0; SEM = 347.0), while SARS-CoV-2-infected SOTRs had a median value of 987.0 BAU/mL (IQR, 45.63–2123.0; SEM = 415.9). Surprisingly, after the third dose, we observed that the uninfected SOTRs had a significant IgA positive serology \( p = 0.0054 \) with a median ratio of 5.4 (IQR, 0.46–7.0; SEM = 0.7), while SOTRs who contracted the infection had a negative IgA serology with a median ratio of 0.56 (IQR, 0.09–1; SEM = 0.4) (Figure 3b).

**Figure 3.** Humoral assessment in uninfected– (n = 27) and infected–vaccinated SOTRs (n = 14) after the third dose of mRNA vaccine. (a) Comparison of IgG Spike (BAU/mL) in uninfected– (white dots) and infected–vaccinated SOTRs (grey dots) after the third booster dose. (b) Comparison of IgA Spike Ratio in uninfected– (white dots) and infected–vaccinated SOTRs (grey dots) after the third booster dose. The dotted line corresponds to the threshold. The significance was determined using the Mann–Whitney U test, ** \( p = 0.0054 \).”

3.6. Humoral Assessment after Breakthrough Infection

Finally, comparing the humoral responses in infected–vaccinated SOTRs at T2 and after SARS-CoV-2 infection (T3), we found a non-significant decrease \( p = 0.9705 \) in the median value of specific IgG after SARS-CoV-2 infection (1.50-fold change), which was 888.9 BAU/mL (IQR, 0.00–2239; SEM = 564.2) at T2 and 590.7 BAU/mL (IQR, 115.5–2332; SEM = 531.5) at T3 (Figure 4a). Concerning serum IgA, the median ratio value was 0.51 (IQR, 0.045–1000; SEM = 0.4160) at T2 and 0.8850 (IQR, 0.5750–1.375; SEM = 0.4) at T3 (Figure 4b). These results suggest that, in the SOTR subgroup who contracted the infection after the third dose, the natural infection did not sufficiently boost either an IgG or IgA humoral response against SARS-CoV-2. Importantly, while these subjects maintain a positive IgG response after three doses of vaccine, they seem to have an impaired ability to mount an anti-Spike-specific IgA response even after the viral infection.
Table 2. Baseline characteristics, humoral and cellular immune response and COVID-19 outcome in 14 SOTRs. SOTRs with a positive humoral or cellular immune response are highlighted in bold. Abbreviations: TX: transplant; MMF: Mycophenolate-mofetil; aVT: antiviral therapy; mAb: monoclonal antibody.

| Basal Characteristics | Immunosuppressive Therapy | Immune Response after 3rd Dose (T2) | Clinical Presentation |
|-----------------------|--------------------------|-------------------------------------|-----------------------|
| Patient (n = 14)      | Age                      | Tx                                  | Years since Tx        |
|                       |                          | Calcineurin INHIBITORS (ng/mL)       | MMF (mg/die)          | Steroid (mg/die) | Anti-Spike IgG (BAU/mL) | Anti-Spike IgA (Ratio) | T Cell Response (SFC/million PBMC) | Symptoms | Treatment | Outcome |
| TxVAC1                | 65                       | liver                               | 27                   | –                  | 1000               | 21.5                    | 0.6                  | 311       | severe    | aVT, steroid | Hospitalized, discharged |
| TxVAC8                | 53                       | lung                                | 8                    | 12.4               | 2000               | 220.9                   | 0.9                  | 320       | moderate  | -         | Nonhospitalized, recovered |
| TxVAC9                | 69                       | lung                                | 1                    | 10.2               | 1000               | 73.3                    | 0.44                 | 0         | severe    | mAb       | Hospitalized, discharged |
| TxVAC11               | 41                       | kidney                              | 3                    | 6.8                | 720                | 6.8                     | 0                    | 0         | severe/critical | mAb, ECMO | Hospitalized, died |
| TxVAC19               | 70                       | kidney                              | 1                    | 6.9                | 1080               | 18.1                    | 0                    | 0         | severe/critical | aVT, mAb | Hospitalized, died |
| TxVAC25               | 41                       | lung                                | 5                    | 10.9               | 2000               | 20.9                    | 0.9                  | 0         | moderate  | aVT       | Nonhospitalized, recovered |
| TxVAC26               | 20                       | lung                                | 6                    | 10.2               | 1000               | 21.6                    | 1                    | 198       | moderate  | -         | Nonhospitalized, recovered |
| TxVAC28               | 58                       | kidney                              | 18                   | 6.4                | 1000               | -                       | 170.8                | 1.03      | 312       | moderate  | -         | Nonhospitalized, recovered |
| TxVAC48               | 50                       | lung                                | 3                    | 7.2                | 500                | 82.9                    | 0.56                 | 9         | severe    | mAb       | Hospitalized, discharged |
| TxVAC66               | 49                       | liver                               | 3                    | 5                  | 250                | 166.4                   | 0.18                 | 839       | moderate  | -         | Nonhospitalized, recovered |
| TxVAC68               | 53                       | liver                               | 11                   | 4.2                | 1000               | -                       | 111                  | 0.46      | 42        | mid       | -         | Nonhospitalized, recovered |
| TxVAC74               | 59                       | heart                               | 12                   | 6.3                | 1000               | -                       | 938.6                | 2.9       | 210       | mild      | -         | Nonhospitalized, recovered |
| TxVAC83               | 40                       | heart                               | 12                   | 6.4                | 1000               | -                       | >1040                | 5.6       | 365       | moderate  | -         | Nonhospitalized, recovered |
| TxVAC85               | 51                       | lung                                | 25                   | 8.8                | 1000               | 5                       | >1040                | 0.8       | 94        | moderate  | -         | Nonhospitalized, recovered |
Among the 14 infected–vaccinated SOTRs, nine did not show a suboptimal ability to respond to the Omicron variant compared with previous variants (from wild type to delta), which, in part, may explain the high numbers of vaccine breakthrough infections [27,28]. Among the 14 infected–vaccinated SOTRs, nine did not show a suboptimal ability to respond to the Omicron variant compared with previous variants (from wild type to delta), which, in part, may explain the high numbers of vaccine breakthrough infections [27,28].

Regarding Spike-specific cellular immune response, we did not observe an improvement after the third dose. In a recent study, however, it was demonstrated that SOTRs receiving the third dose after 2 months from the second dose showed an improved Spike-specific T cell response [25]. The reason we did not observe a significant improvement in the T cell response in our SOTRs can be due to the time elapsed between the second and third doses of the vaccine, which was greater than 3 months, since it has been described that SARS-CoV-2-specific T cells decline with a half-life of 3 to 5 months after natural infection or first vaccination cycle [26]. Nevertheless, the third booster dose induced an increase from 77 to 90% in total response in SOTRs, merging humoral and cellular immune responses. This result is also confirmed by the increased significant correlation magnitude existing between the cellular response and the IgG antibody levels. Moreover, in our cohort of SOTRs, the type of immunosuppressive regimen does not appear to have a significant impact on immune response. During follow-up, none of the SOTRs included in the study reported infection until after the administration of the third dose. At a median time of 130 days from the third dose, during the Omicron wave, 14/43 (32%) patients contracted the infection. Recently, it was reported that even with three doses of mRNA vaccine, SOTRs show a suboptimal ability to respond to the Omicron variant compared with previous variants (from wild type to delta), which, in part, may explain the high numbers of vaccine breakthrough infections [27,28]. Among the 14 infected–vaccinated SOTRs, nine did not show a suboptimal ability to respond to the Omicron variant compared with previous variants (from wild type to delta), which, in part, may explain the high numbers of vaccine breakthrough infections [27,28].
need hospitalization and showed mild to moderate symptoms, three SOTRs showed severe symptoms that required hospitalization and subsequently recovered, and two had a fatal outcome. The remaining 29 vaccinated SOTRs who did not contract the infection showed positivity for both IgG and IgA anti-SARS-CoV-2 antibodies. Despite maintaining anti-SARS-CoV-2 IgG positivity similar to their uninfected–vaccinated counterparts, almost all infected–vaccinated SOTRs were negative for anti-Spike IgA. Surprisingly, these subjects did not show a positive IgA serology even after natural infection. IgA antibodies, which account for 10 to 15% of human immunoglobulins [29], are known to play a central role in mucosal immunity, which is important in protection against respiratory infections, such as SARS-CoV-2. It was recently demonstrated that the presence of serological IgA is superior to IgM as an early serological marker of recent SARS-CoV-2 infection, demonstrating the importance of IgA in the disease progression [30,31] and in the prediction of the clinical course of COVID-19 [32]. In addition, we recently reported that both the first vaccination cycle and the booster dose of the anti-SARS-CoV-2 mRNA vaccine can induce a strong anti-Spike-specific serological IgA response in immunocompetent subjects [33]. Our results on infected–vaccinated SOTRs, together with these recent findings, lead us to speculate that these subjects are probably more susceptible to contracting the infection compared with those who are not infected, who show a positive IgA serology. For this reason, we suggest that serum IgA detection can be helpful, along with the detection of IgG, for the evaluation of vaccine efficacy, mainly in fragile subjects at high risk of infection, such as SOTRs. The limitations of our study are the small cohort of SOTRs studied, and the heterogeneity in the type of transplanted organs and of the immunosuppressive therapies.

5. Conclusions

We can conclude that, despite three doses of vaccine, SOTRs remain at risk of severe COVID-19 supporting the necessity for continued efforts to limit the risk of COVID-19 in this population [24]. The fourth dose of mRNA COVID-19 vaccines is now recommended for immunocompromised individuals. Future studies will be important for understanding the effectiveness of the fourth dose in preventing hospitalization, the residual risk of severe COVID-19 among SOTRs, and the durability of protection. Additional booster doses or modified vaccines, through the addition of adjuvants or increasing antigens [24], can provide the benefit of overcoming the impaired immune response observed in SOTRs. Finally, taking additional precautions to mitigate the risk of SARS-CoV-2 exposure among SOTRs, such as constant monitoring of the SARS-CoV-2-specific immune response, remain of crucial importance.

Author Contributions: Conceptualization, M.M., R.B. and M.B.; methodology, M.M., R.B., M.B., M.D.B., F.T., G.V. and M.C.S.; software, R.B.; formal analysis, G.R.; investigation, A.M., P.V. and E.C.; resources, P.G.C.; data curation, M.M., R.B., M.B. and G.R.; writing—original draft preparation, M.M., R.B. and M.B.; writing—review and editing, M.B. and M.M.; visualization, R.B.; supervision, P.G.C.; project administration, M.B.; funding acquisition, P.G.C. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by Ministero della Salute Ricerca Finalizzata Progetto COVID-2020-12371760 and Ministero della Salute a valere sui fondi Ricerca Corrente Reti 2020 (RCR-2020): Rete Tematica IRCCS—Rete Cardiologica, grant number 23670065.

Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Review Board and Ethics Committee of IRCCS ISMETT (protocol code IRBB 00/2, 24 March 2021).

Data Availability Statement: The original contributions presented in the study are included in the article. Further inquiries can be directed to the corresponding authors.

Acknowledgments: The authors thank Danilo Romeres and his colleagues of ISMETT’s Language Services Department for his language editing of the manuscript.
Conflicts of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationship that could be construed as a potential conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data, in the writing of the manuscript, or in the decision to publish the results.

References

1. Dagan, N.; Barda, N.; Kepten, E.; Miron, O.; Perchik, S.; Katz, M.A.; Herman, M.A.; Lipsitch, M.; Reis, B.; Balicer, R.D. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N. Engl. J. Med. 2021, 384, 1412–1423. [CrossRef]
2. Haas, E.J.; Angulo, F.J.; McLaughlin, J.M.; Anis, E.; Singer, S.R.; Khan, F.; Brooks, N.; Smaja, M.; Marcus, G.; Fan, K.; et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: An observational study using national surveillance data. Lancet 2021, 397, 1819–1829. [CrossRef]
3. Lauring, A.S.; Tenforde, M.W.; Chappell, J.D.; Gaglani, M.; Ginde, A.A.; McNeal, T.; Ghamande, S.; Douin, D.J.; Talbot, H.K.; Casevitz, R.; et al. Clinical severity of, and effectiveness of mRNA vaccines against, COVID-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: Prospective observational study. BMJ 2022, 376, e669761. [CrossRef] [PubMed]
4. Young-Xu, Y.; Korves, C.; Roberts, J.; Powell, E.L.; Zwain, G.M.; Smith, J.; Izurieta, H.S. Coverage and Estimated Effectiveness of mRNA COVID-19 Vaccines Among US Veterans. JAMA Netw. Open 2021, 4, e2128391. [CrossRef] [PubMed]
5. Grupper, A.; Rabinowich, L.; Schwartz, D.; Schwartz, I.F.; Ben-Yehoyada, M.; Shashar, M.; Katchman, E.; Halperin, T.; Turner, D.; Goykhman, Y.; et al. Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus. Am. J. Transplant. 2021, 21, 2719–2726. [CrossRef] [PubMed]
6. Guarino, M.; Cossiga, V.; Esposito, I.; Furrno, A.; Morisco, F. Effectiveness of SARS-CoV-2 vaccination in liver transplanted patients: The debate is open! J. Hepatol. 2022, 76, 237–239. [CrossRef] [PubMed]
7. Marinaki, S.; Adamopoulos, S.; Degiannis, D.; Roussos, S.; Pavlopoulou, I.D.; Hatzakis, A.; Boletis, I.N. Immunogenicity of SARS-CoV-2 BNT162b2 vaccine in solid organ transplant recipients. Am. J. Transplant. 2021, 21, 2913–2915. [CrossRef]
8. Young, D.; Bello, A.; Abravanel, F.; Couta, C.; Faguer, S.; Esposito, L.; Hebral, A.L.; Izopet, J.; Kamar, N. Safety and Immunogenicity of Anti-SARS-CoV-2 Messenger RNA Vaccines in Recipients of Solid Organ Transplants. Ann. Intern. Med. 2021, 174, 1336–1338. [CrossRef]
9. Miele, M.; Busa, R.; Russelli, G.; Sorrentino, M.C.; Di Bella, M.; Timoneri, F.; Mularoni, A.; Panarello, G.; Vitulo, P.; Conaldi, P.G.; et al. Impaired anti-SARS-CoV-2 humoral and cellular immune response induced by Pfizer-BioNTech BNT162b2 mRNA vaccine in solid organ transplanted patients. Am. J. Transplant. 2021, 21, 2919–2921. [CrossRef]
10. Rincon-Arevalo, H.; Choi, M.; Stefanski, A.L.; Halleck, F.; Weber, U.; Szelinski, F.; Jahrsdorfer, B.; Schrezenmeier, H.; Ludwig, C.; Sattler, A.; et al. Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients. Sci. Immunol. 2021, 6, eabi1031. [CrossRef]
11. Gummert, J. Poor humoral and T-cell response to two-dose SARS-CoV-2 messenger RNA vaccine BNT162b2 in cardiothoracic transplant recipients. Clin. Res. Cardiol. 2021, 110, 1142–1149. [CrossRef] [PubMed]
12. Haddadin, Z.; Krueger, K.; Thomas, L.D.; Overton, E.T.; Ison, M.; Halasa, N. Alternative strategies of posttransplant influenza vaccination in adult solid organ transplant recipients. Am. J. Transplant. 2021, 21, 938–949. [CrossRef] [PubMed]
13. Hirzel, C.; Kumar, D. Influenza vaccine strategies for solid organ transplant recipients. Curr. Opin. Infect. Dis. 2018, 31, 309–315. [CrossRef] [PubMed]
14. Mombelli, M.; Kampouri, E.; Manuel, O. Influenza in solid organ transplant recipients: Epidemiology, management, and outcomes. Expert Rev. Anti-Infect. Ther. 2020, 18, 103–112. [CrossRef] [PubMed]
15. Galmiche, S.; Luong Nguyen, L.B.; Tartour, E.; de Lamballerie, X.; Wittkop, L.; Loubet, P.; Launay, O. Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: A systematic review. Clin. Microbiol. Infect. 2022, 28, 163–177. [CrossRef] [PubMed]
16. Del Bello, A.; Abravanel, F.; Marion, O.; Couta, C.; Esposito, L.; Lavayssiëre, L.; Izopet, J.; Kamar, N. Efficiency of a boost with a third dose of anti-SARS-CoV-2 messenger RNA-based vaccines in solid organ transplant recipients. Am. J. Transplant. 2022, 22, 322–323. [CrossRef] [PubMed]
17. Peled, Y.; Ram, E.; Lavee, J.; Segev, A.; Matezki, S.; Wieder-Finesod, A.; Halperin, R.; Mandelboim, M.; Indenbaum, V.; Levy, I.; et al. Third dose of the BNT162b2 vaccine in heart transplant recipients: Immunogenicity and clinical experience. J. Heart Lung Transplant. 2022, 41, 148–157. [CrossRef]
18. Boekel, L.; Steenhuis, M.; Hooijberg, F.; Besten, Y.R.; van Kempen, Z.L.E.; Kummer, L.Y.; van Dam, K.P.J.; Stalman, E.W.; Vogelzang, E.H.; Cristianawati, O.; et al. Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: A subsity of data from two prospective cohort studies. Lancet Rheumatol. 2021, 3, e778. [CrossRef]
19. Deepak, P.; Kim, W.; Paley, M.A.; Yang, M.; Carvildi, A.B.; Demissie, E.G.; El-Qunni, A.A.; Haile, A.; Huang, K.; Kinnett, B.; et al. Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2: A Prospective Cohort Study. Ann. Intern. Med. 2021, 174, 1572–1585. [CrossRef] [PubMed]
20. Massarweh, A.; Eliakim-Raz, N.; Stemmer, A.; Levy-Barda, A.; Yust-Katz, S.; Zer, A.; Benouaich-Amiel, A.; Ben-Zvi, H.; Moskovits, N.; Brenner, B.; et al. Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer. *JAMA Oncol.* 2021, 7, 1133–1140. [CrossRef]  

21. Tenforde, M.W.; Patel, M.M.; Gaglani, M.; Ginde, A.A.; Douin, D.J.; Talbot, H.K.; Casey, J.D.; Mohr, N.M.; Zepeski, A.; McNeal, T.; et al. Effectiveness of a Third Dose of Pfizer-BioNTech and Moderna Vaccines in Preventing COVID-19 Hospitalization Among Immunocompetent and Immunocompromised Adults—United States, August–December. *MMWR. Morb. Mortal. Wkly. Rep.* 2022, 71, 118–124. [CrossRef] [PubMed]  

22. Tenforde, M.W.; Self, W.H.; Adams, K.; Gaglani, M.; Ginde, A.A.; McNeal, T.; Ghamande, S.; Douin, D.J.; Talbot, H.K.; Casey, J.D.; et al. Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity. *JAMA* 2021, 326, 2043–2054. [CrossRef] [PubMed]  

23. Janetzki, S.; Price, L.; Schroeder, H.; Britten, C.M.; Welters, M.J.; Hoos, A. Guidelines for the automated evaluation of Elispot assays. *Nat. Protoc.* 2015, 10, 1098–1115. [CrossRef] [PubMed]  

24. Kwon, J.H.; Tenforde, M.W.; Gaglani, M.; Talbot, H.K.; Ginde, A.A.; McNeal, T.; Ghamande, S.; Douin, D.J.; Casey, J.D.; Mohr, N.M.; et al. mRNA Vaccine Effectiveness Against COVID-19 Hospitalization Among Solid Organ Transplant Recipients. *J. Infect. Dis.* 2022, jiac118. [CrossRef] [PubMed]  

25. Hall, V.G.; Ferreira, V.H.; Ku, T.; Ierullo, M.; Majchrzak-Kita, B.; Chaparro, C.; Selzner, N.; Schiff, J.; McDonald, M.; Tomlinson, G.; et al. Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients. *N. Engl. J. Med.* 2021, 385, 1244–1246. [CrossRef] [PubMed]  

26. Dan, J.M.; Mateus, J.; Kato, Y.; Hastie, K.M.; Yu, E.D.; Faliiti, C.E.; Grifoni, A.; Ramirez, S.I.; Haupt, S.; Frazier, A.; et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. *Science* 2021, 371, eabf4063. [CrossRef]  

27. Al Jurdi, A.; Gassen, R.B.; Borges, T.J.; Lape, I.T.; Morena, L.; Efe, O.; Solhiou, Z.; El Fekih, R.; Deban, C.; Bohan, B.; et al. Suboptimal antibody response against SARS-CoV-2 Omicron variant after third dose of mRNA vaccine in kidney transplant recipients. *Kidney Int.* 2022, 101, 1282–1286. [CrossRef]  

28. Kumar, D.; Hu, Q.; Samson, R.; Ferreira, V.H.; Hall, V.G.; Ierullo, M.; Majchrzak-Kita, B.; Hardy, W.; Gingras, A.C.; Humar, A. Neutralization against Omicron variant in transplant recipients after three doses of mRNA vaccine. *Am. J. Transplant.* 2022. [CrossRef]  

29. Wang, P. Significance of IgA antibody testing for early detection of SARS-CoV-2. *J. Med. Virol.* 2021, 93, 1888–1889. [CrossRef] [PubMed]  

30. Infantino, M.; Manfredi, M.; Grossi, V.; Lari, B.; Fabbri, S.; Benucci, M.; Fortini, A.; Damiani, A.; Mobilia, E.M.; Pancirolli, M.; et al. Closing the serological gap in the diagnostic testing for COVID-19: The value of anti-SARS-CoV-2 IgA antibodies. *J. Med. Virol.* 2021, 93, 1436–1442. [CrossRef]  

31. Yu, H.Q.; Sun, B.Q.; Fang, Z.F.; Zhao, J.C.; Liu, X.Y.; Li, Y.M.; Sun, X.Z.; Liang, H.F.; Zhong, B.; Huang, Z.F.; et al. Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients. *Eur. Respir. J.* 2020, 56, 2001526. [CrossRef] [PubMed]  

32. Siracusano, G.; Brombin, C.; Pastori, C.; Cugnata, F.; Noviello, M.; Tassi, E.; Princi, D.; Cantoni, D.; Malnati, M.S.; Maugeri, N.; et al. Profiling Antibody Response Patterns in COVID-19: Spike S1-Reactive IgA Signature in the Evolution of SARS-CoV-2 Infection. *Front. Immunol.* 2021, 12, 772239. [CrossRef] [PubMed]  

33. Busa, R.; Sorrentino, M.C.; Russelli, G.; Amico, G.; Miceli, V.; Miele, M.; Di Bella, M.; Timoneri, F.; Gallo, A.; Zito, G.; et al. Specific Anti-SARS-CoV-2 Humoral and Cellular Immune Responses After Booster Dose of BNT162b2 Pfizer-BioNTech mRNA-Based Vaccine: Integrated Study of Adaptive Immune System Components. *Front. Immunol.* 2022, 13, 856657. [CrossRef] [PubMed]